Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.4% Higher - Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares rose 0.4% during mid-day trading on Friday . The stock traded as high as $7.14 and last traded at $7.01. Approximately 2,920,923 shares changed hands during mid-day trading, a decline of 55% from the average daily volume of 6,469,048 shares. The stock had previously closed at $6.98.

Analyst Ratings Changes

RXRX has been the topic of several analyst reports. Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday. Finally, Jefferies Financial Group dropped their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a research report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Recursion Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Performance

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.98 billion, a P/E ratio of -4.58 and a beta of 0.85. The business has a 50 day moving average price of $6.71 and a two-hundred day moving average price of $7.29.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period in the previous year, the company posted ($0.43) earnings per share. Recursion Pharmaceuticals's quarterly revenue was up 147.6% on a year-over-year basis. On average, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $6.84, for a total value of $78,297.48. Following the sale, the director now owns 7,109,875 shares of the company's stock, valued at $48,631,545. The trade was a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the sale, the chief executive officer now owns 762,656 shares of the company's stock, valued at approximately $4,697,960.96. This trade represents a 2.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 119,235 shares of company stock valued at $802,988 in the last three months. 15.75% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC boosted its position in Recursion Pharmaceuticals by 16.4% during the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company's stock worth $215,949,000 after acquiring an additional 4,626,268 shares during the period. Baillie Gifford & Co. lifted its position in shares of Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company's stock worth $199,425,000 after buying an additional 2,522,132 shares during the last quarter. State Street Corp lifted its position in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. FMR LLC grew its position in Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company's stock worth $55,116,000 after purchasing an additional 170,810 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock valued at $35,803,000 after purchasing an additional 656,003 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.